468-Beyond GLP-1 Series: A Triumph Of Marketing Over Patient Care With Louise Adams

The drugs have been sold as a miracle. The science has been quietly shaped by the companies profiting from them. And the deaths are not yet being called a scandal.Clinical psychologist Louise Adams co-authored a paper that has already been read more than 7,500 times in its first ten days. She joins me to trace the three-pronged pharmaceutical marketing strategy behind GLP-1 drugs, follow the money through conflict-of-interest research, celebrity spokespeople, and government lobbying, and tell us what real informed consent would actually require.In this episode you will learn:The 2015 Novo Nordisk marketing roadmap that predicted everything we are living through nowWhy many obesity researchers are now functioning as pharmaceutical sales representativesWhat weight cycling is and why it is missing from the GLP-1 conversationWhat a health professional's informed consent process should look likeWhy Louise is cautiously optimistic that GLP-1 research will inadvertently strengthen the case for weight inclusive medicine in the next decadEMentioned in the show:Listen to the entire Beyond GLP-1 podcast series: https://program.stephaniedodier.com/beyond-glp-1Louise Adams' paper: GLP-1 medication for weight loss, a triumph of marketing over patient care -- https://www.tandfonline.com/doi/full/10.1080/21604851.2026.2646492Louise Adams -- meet Louise and her work: https://untrapped.com.au/meet-louise/Louise Adams' newsletter and podcast All Fired Up: untrapped.com.auRagen Chastain's Weight and Healthcare Substack: weightandhealthcare.substack.comAWIM GLP-1 Informed Consent document: https://sizeinclusivemedicine.org/wp-content/uploads/2023/11/MSSI-GLP1-Informed-Consent-1-1.pdfHAES Health Sheets: https://haeshealthsheets.com/Non-Diet Coaching Assessment Tool: stephaniedodier.com/clientassessmentThe Groundwork waitlist: https://program.stephaniedodier.com/groundwork